November 13, 2019 7:48am
…. Who gets to pull the Fed chair’s seat?
Federal Reserve Chairman, Jerome Powell, will address the Joint Economic Committee at 11:00 a.m. ET.
News; The usual response, as Solid Biosciences (SLDB –$8.18 or -74.36% )got slammed with massive volume , Sarepta Therapeutics (SRPT +5.5% to $99.95) jumped skyward on low volume. SRPT has dosed at least 16 patients to date at (one dose), with no clinical holds,
How does the old Ben Graham quote go? "In the short run, the market is a voting machine but in the long run it is a weighing machine"?
My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future
Dow futures are DOWN -0.39% (-108 points), S&P futures are DOWN -0.38% (-12 points) and NASDAQ futures are DOWN -0.45% (-38 points)
U.S. stock index futures were lower;
European stocks traded lower amid concern over U.S.-China trade talks, escalating unrest in Hong Kong, and the “words” from U.S. Fed Chair Powell as the pan-European Stoxx 600 was down -0.7%;
Asia Pacific stocks were lower with Hong Kong stocks declining as a recent escalation in violence amid ongoing protests weighed on investor sentiment with the MSCI Asia ex-Japan index -1.05% lower.
Data Docket: CPI numbers at 08:30 a.m. ET and Federal Budget figures released at 02:00 p.m. ET.
Market “players” are weighing the prospects of a trade deal between China and the U.S.
The “White House” ,claimed that the initial phase of a trade deal between the world’s two largest economies would be completed “soon” but offered no new details while branding China “cheaters.”
Tuesday night’s newsletter heading: “a lot of pitches and many strikes today”
Last night’s numbers: https://www.regmedinvestors.com/articles/11101
My response for today's action: sidelines!!
Review the context of Q4’s market – so far:
- November has registered 4 positive and 4 negative close;
- October registered 10 positive, 1 neutral and 14 negative closes;
Companies in my headlights – It’s your decision; I provide an idea and context:
*** I can’t change my “tune” … be mindful of upcoming quarterly results and their effect upon share pricing … BUY and get trampled in the coming sessions or SELL into strength or just HOLD and wait to resolve relieve the earnings estimates and expectation anxiety.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.